Directory
>
Andrew Kolodziej
Andrew Kolodziej
Executive Director, Regulatory Toxicology | Corbus Pharmaceuticals
Cambridge, Massachusetts, United States
Andrew Kolodziej
Summary
Andrew Kolodziej is a seasoned professional in regulatory toxicology and translational pharmacology, currently serving as the Executive Director at Corbus Pharmaceuticals. With a robust background in drug development, he has specialized expertise in early-stage discovery through Phase 2 development, focusing on toxicology and regulatory submissions. His experience spans various disease areas, including cardiovascular diseases and oncology, with a particular interest in protein homeostasis related to conditions like Cystic Fibrosis and Alzheimer's. Andrew has a proven track record in leading teams and managing complex projects, having held senior roles in multiple organizations, including Keros Therapeutics and Flatley Discovery Lab. He is a co-inventor of innovative MRI contrast imaging agents and has secured significant funding for research initiatives. Andrew's academic foundation includes a Ph.D. in Chemistry from MIT and a B.S. from the University of Chicago, underscoring his strong scientific acumen. His passion for advancing therapeutics is evident in his ongoing contributions to the field, particularly in the development of biomarkers and novel drug compounds.
Andrew Kolodziej
Work Experience
Executive Director, Regulatory Toxicology at
Corbus Pharmaceuticals
July 2020 - Present
Sr. Director Toxicology at
Keros Therapeutics
July 2019 - October 2019
Vice President, Nonclinical Safety and CMC at
Flatley Discovery Lab
November 2015 - July 2019
Vice President, Research at
Flatley Discovery Lab
November 2011 - November 2015
Consulting Director of Research at
COLLAGEN MEDICAL, LLC
January 2011 - November 2011
Director, Drug Discovery and Development at
Eutropics
July 2009 - December 2010
Project Leader at
EPIX Pharmaceuticals
January 2007 - January 2009
Scientist at
EPIX Pharmaceuticals
January 1996 - January 2008
Post Doctoral Fellow at
University Of California Berkeley
January 1991 - January 1996
Graduate Student at
Mit
January 1985 - January 1991
Student at
University Of Chicago
January 1982 - January 1985
Andrew Kolodziej
Education
Massachusetts Institute of Technology, Ph.D.
January 1989 - January 1991
University of Chicago, B.S.
January 1981 - January 1985
University High school
Frequently Asked Questions about Andrew Kolodziej
What is Andrew Kolodziej email address?
Andrew Kolodziej's primary email address is **********@corbuspharma.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Andrew Kolodziej work for?
Andrew Kolodziej is a Executive Director, Regulatory Toxicology at Corbus Pharmaceuticals, a company specializing in Biological products, except diagnostic.
Where Andrew Kolodziej graduated from?
Andrew Kolodziej holds a degree in Chemistry from Massachusetts Institute of Technology.
How can I directly contact Andrew Kolodziej?
To contact Andrew Kolodziej directly, you can use the email address **********@corbuspharma.com. Complete contact information is available upon registration with Muraena.
Who is Andrew Kolodziej?
Andrew Kolodziej is a seasoned professional in regulatory toxicology and translational pharmacology, currently serving as the Executive Director at Corbus Pharmaceuticals. With a robust background in drug development, he has specialized expertise in early-stage discovery through Phase 2 development, focusing on toxicology and regulatory submissions. His experience spans various disease areas, including cardiovascular diseases and oncology, with a particular interest in protein homeostasis related to conditions like Cystic Fibrosis and Alzheimer's. Andrew has a proven track record in leading teams and managing complex projects, having held senior roles in multiple organizations, including Keros Therapeutics and Flatley Discovery Lab. He is a co-inventor of innovative MRI contrast imaging agents and has secured significant funding for research initiatives. Andrew's academic foundation includes a Ph.D. in Chemistry from MIT and a B.S. from the University of Chicago, underscoring his strong scientific acumen. His passion for advancing therapeutics is evident in his ongoing contributions to the field, particularly in the development of biomarkers and novel drug compounds.
Andrew`s contact details
**********@corbuspharma.com
Colleagues
Board Member
Chief Financial Officer
Chief Executive Officer
Vice President of Finance